Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$1175.00
-15.00 (-1.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-31.5B · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$173.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-5.0%
↓Gross Margin
57.9%
↑Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.6%
FCF CAGR
—
FCF margin
-41.8%
FCF / Net income
4.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $105.23B · net income $-10.08B · FCF $-44.03B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $105.23B | $105.23B | $99.10B | $93.91B | $82.20B |
| Net Income | $-10.08B | $-10.08B | $2.69B | $6.46B | $-388.1M |
| EBITDA | $-5.59B | $-5.59B | $8.74B | $9.37B | $1.04B |
| EPS | -70.00 | -70.00 | 5.00 | 46.00 | -3.00 |
| Gross Margin | 57.9% | 57.9% | 46.1% | 46.5% | 49.8% |
| Operating Margin | -3.5% | -3.5% | 0.3% | 3.2% | 3.6% |
| Net Margin | -9.6% | -9.6% | 2.7% | 6.9% | -0.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.36 | 0.36 | 0.42 | 0.14 | 0.04 |
| Current Ratio | 1.25 | 1.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-44.03B | $-44.03B | $-31.46B | $-11.34B | $-5.37B |
| Returns | |||||
| ROE | -5.0% | -5.0% | 1.4% | 3.4% | -0.2% |
| Valuation | |||||
| P/E | — | — | 360.80 | 51.20 | — |
| EV/EBITDA | — | — | 41.29 | 37.93 | 269.72 |
| P/B | 0.84 | 0.84 | 1.50 | 1.74 | 1.51 |
| Growth & Yield | |||||
| Revenue Growth | 6.2% | 6.2% | 5.5% | 14.2% | — |
| EPS Growth | -1500.0% | -1500.0% | -89.1% | 1633.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-47.2%
Start / end P/E
n/dx → n/dx
EPS bridge
5.00 → -70.00
Residual
-47.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.